Report of Novel and Known Variants with Variable Presentations

Danai Veltra,Virginia Theodorou,Marina Katsalouli,Pelagia Vorgia,Georgios Niotakis,Triantafyllia Tsaprouni,Roser Pons,Konstantina Kosma,Afroditi Kampouraki,Irene Tsoutsou,Periklis Makrythanasis,Kyriaki Kekou,Joanne Traeger-Synodinos,Christalena Sofocleous

DOI: https://doi.org/10.3390/ijms25115644

IF: 5.6

2024-05-23

International Journal of Molecular Sciences

Abstract:SCN1A, the gene encoding for the Nav1.1 channel, exhibits dominant interneuron-specific expression, whereby variants disrupting the channel's function affect the initiation and propagation of action potentials and neuronal excitability causing various types of epilepsy. Dravet syndrome (DS), the first described clinical presentation of SCN1A channelopathy, is characterized by severe myoclonic epilepsy in infancy (SMEI). Variants' characteristics and other genetic or epigenetic factors lead to extreme clinical heterogeneity, ranging from non-epileptic conditions to developmental and epileptic encephalopathy (DEE). This current study reports on findings from 343 patients referred by physicians in hospitals and tertiary care centers in Greece between 2017 and 2023. Positive family history for specific neurologic disorders was disclosed in 89 cases and the one common clinical feature was the onset of seizures, at a mean age of 17 months (range from birth to 15 years old). Most patients were specifically referred for SCN1A investigation (Sanger Sequencing and MLPA) and only five for next generation sequencing. Twenty-six SCN1A variants were detected, including nine novel causative variants (c.4567A>Τ, c.5564C>A, c.2176+2T>C, c.3646G>C, c.4331C>A, c.1130_1131delGAinsAC, c.1574_1580delCTGAGGA, c.4620A>G and c.5462A>C), and are herein presented, along with subsequent genotype–phenotype associations. The identification of novel variants complements SCN1A databases extending our expertise on genetic counseling and patient and family management including gene-based personalized interventions.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is related to the relationship between SCN1A gene variants and epilepsy phenotypes. Specifically, the study aims to analyze SCN1A gene variants in a group of patients to explore how these variants lead to different types of epilepsy phenotypes, including a wide range from non - epileptic states to developmental and epileptic encephalopathy (DEE). The study also focuses on the discovery of new and known variants and their impact on clinical manifestations, and how these findings enrich the SCN1A database and improve the understanding of patient diagnosis, prognosis, and management.

### Research Background
The SCN1A gene encodes the Nav1.1 sodium channel, which is specifically expressed in the central nervous system, especially in the dendrites and cell bodies of excitatory neurons. Variations in the SCN1A gene can affect the initiation and propagation of action potentials, thereby affecting neuronal excitability and leading to multiple types of epilepsy. Among them, Dravet syndrome (DS) is one of the earliest described clinical manifestations of SCN1A channelopathy, characterized by severe myoclonic epilepsy in infancy (SMEI). However, the characteristics of SCN1A gene variants and other genetic or epigenetic factors can lead to extreme clinical heterogeneity, ranging from non - epileptic states to DEE.

### Research Objectives
1. **Analyze SCN1A gene variants**: Through genetic testing of 343 patients, identify new and known variants of the SCN1A gene.
2. **Explore genotype - phenotype associations**: Study how these variants affect the clinical manifestations of patients, especially different types of epilepsy phenotypes.
3. **Enrich the SCN1A database**: Incorporate newly discovered variants into the SCN1A database to support genetic counseling and patient management.
4. **Improve the level of diagnosis and treatment**: Through the study of genotype - phenotype associations, provide more accurate diagnosis and treatment recommendations for clinicians.

### Main Findings
- **Discovery of new variants**: 26 SCN1A variants were discovered in the study, including 9 new pathogenic variants.
- **Diversity of clinical manifestations**: The clinical manifestations of patients range from mild febrile seizures to severe DEE, showing great clinical heterogeneity.
- **Genotype - phenotype associations**: Variations at certain specific positions (such as the S4, S5 - S6 regions) are associated with more severe phenotypes, while variations at other positions may lead to milder phenotypes.

### Conclusions
This study not only expands the understanding of SCN1A gene variants and their clinical manifestations but also provides important data support for future genetic counseling and patient management. Through these findings, individualized treatment and management can be better carried out, and the quality of life of patients can be improved.